Last reviewed · How we verify
Bioequivalence Study of Paroxetine Immediate Release (IR) Tablets Manufactured in GlaxoSmithKline Tianjin (GSKT) and Mississauga Sites in Healthy Chinese Subjects
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) and paroxetine IR tablets have been approved for the treatment of three anxiety indications in China. This bioequivalence study will evaluate Paroxetine IR tablets manufactured in GSKT (A) and Mississauga (B) sites in healthy Chinese subjects under fasting and fed conditions to support the quality consistency evaluation. This is a single dose, open-label, randomized, two-period crossover study and will include a screening period (up to 7 days), two open-label treatment periods (up to 16 days) and a follow-up phase (up to 14 days after last-dose). The whole study will be divided into two groups, one for fasting condition enrolling approximately 36 subjects and another for fed condition for which approximately 44 subjects will be enrolled. In both groups, eligible subjects will be randomized to receive single dose of Paroxetine IR tablets A or B in a cross-over manner.
Details
| Lead sponsor | GlaxoSmithKline |
|---|---|
| Phase | PHASE1 |
| Status | COMPLETED |
| Enrolment | 85 |
| Start date | Wed May 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Aug 03 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Anxiety Disorders
Interventions
- Paroxetine IR tablets A
- Paroxetine IR tablets B
Countries
China